Pfizer Lipitor Patent Claiming Crystalline Atorvastatin Is Valid, PTO Says
This article was originally published in The Pink Sheet Daily
Executive SummaryThe Public Patent Foundation nevertheless asserts victory, saying Pfizer was forced to narrow the claims for the '156 patent.
You may also be interested in...
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
Sponsor seeks accelerated approval for low-risk, early-stage prostate cancer based on a trial that met its coprimary endpoints, but agency says interpretation of those results is complicated by novelty of the outcomes, data quality issues and increase in genitourinary adverse events.